Commentary

You have free access to this content

Building bone with a SOST-PTH partnership

  1. Natalie A Sims*

Article first published online: 1 FEB 2010

DOI: 10.1002/jbmr.53

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 2, pages 175–177, February 2010

Additional Information

How to Cite

Sims, N. A. (2010), Building bone with a SOST-PTH partnership. Journal of Bone and Mineral Research, 25: 175–177. doi: 10.1002/jbmr.53

Author Information

  1. St. Vincent's Institute and Department of Medicine at St. Vincent's Hospital, The University of Melbourne, Fitzroy, Victoria, Australia

*Sims, St. Vincent's Institute, 9 Princes Street, Fitzroy, Victoria 3065, Australia.

Publication History

  1. Issue published online: 19 FEB 2010
  2. Article first published online: 1 FEB 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (57K)

References

  • 1
    van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005; 16: 319–327.
  • 2
    Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280: 19883–19887.
  • 3
    Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005; 37: 148–158.
  • 4
    Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010; 25: 178–189.
  • 5
    Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone(1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344: 1434–1441.
  • 6
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone(1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18: 1932–1941.
  • 7
    Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995; 136: 3632–3638.
  • 8
    Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104: 439–446.
  • 9
    Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med. 2005; 11: 76–81.
  • 10
    Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146: 4577–4583.
  • 11
    Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005; 15: 928–935.
  • 12
    Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10: 537–543.
  • 13
    Yamashita J, Datta NS, Chun YH, et al. Role of Bcl2 in osteoclastogenesis and PTH anabolic actions in bone. J Bone Miner Res. 2008; 23: 621–632.
  • 14
    Terauchi M, Li JY, Bedi B, et al. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab. 2009; 10: 229–240.
  • 15
    Raggatt LJ, Qin L, Tamasi J, et al. Interleukin-18 is regulated by parathyroid hormone and is required for its bone anabolic actions. J Biol Chem. 2008; 283: 6790–6798.
  • 16
    Hurley MM, Okada Y, Xiao L, et al. Impaired bone anabolic response to parathyroid hormone in Fgf2−/− and Fgf2+/− mice. Biochem Biophys Res Commun. 2006; 341: 989–994.
  • 17
    Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology. 2001; 142: 4349–4356.
  • 18
    Yu S, Franceschi RT, Luo M, et al. Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone. PLoS One. 2009; 4: e7583.
  • 19
    Kogianni G, Mann V, Noble BS. Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction. J Bone Miner Res. 2008.
  • 20
    Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone. 2009; 44: 275–286.
  • 21
    Onyia JE, Helvering LM, Gelbert L, et al. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J Cell Biochem. 2005; 95: 403–418.
  • 22
    Allan EH, Hausler KD, Wei T, et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res. 2008; 23: 1170–1181.
  • 23
    Li X, Liu H, Qin L, et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem. 2007; 282: 33086–33097.
  • 24
    Liu F, Lee SK, Adams DJ, Gronowicz GA, Kream BE. CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment. Bone. 2007; 40: 1135–1143.
  • 25
    Ferrari SL, Pierroz DD, Glatt V, et al. Bone response to intermittent parathyroid hormone is altered in mice null for β-arrestin2. Endocrinology. 2005; 146: 1854–1862.
  • 26
    Wang Y, Nishida S, Boudignon BM, et al. IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res. 2007; 22: 1329–1337.
  • 27
    Machado do, Reis L, Kessler CB, Adams DJ, Lorenzo J, Jorgetti V, Delany AM. Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice. Bone. 2008; 43: 264–273.
  • 28
    Yao W, Cheng Z, Shahnazari M, Dai W, Johnson ML, Lane NE. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res. 2010; 25: 190–199.
  • 29
    Bodine PV, Seestaller-Wehr L, Kharode YP, Bex FJ, Komm BS. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol. 2007; 210: 352–357.
  • 30
    Iwaniec UT, Wronski TJ, Liu J, et al. PTH stimulates bone formation in mice deficient in Lrp5. J Bone Miner Res. 2007; 22: 394–402.
  • 31
    Sawakami K, Robling AG, Ai M, et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2006; 281: 23698–23711.
  • 32
    Miao D, He B, Jiang Y, et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1–34. J Clin Invest. 2005; 115: 2402–2411.
  • 33
    Robling AG, Bellido T, Turner CH. Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskel Neuronal Interact. 2006; 6: 354.
  • 34
    Walker EC, McGregor NE, Poulton IJ, et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest. 2010; 120: 582–592.
  • 35
    Eddleston A, Marenzana M, Moore AR, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res. 2009; 24: 1662–1671.
  • 36
    Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24: 578–588.
  • 37
    Richards JB, Kavvoura FK, Rivadeneira F, et al. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med. 2009; 151: 528–537.
  • 38
    Huang QY, Li GH, Kung AW. The –9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPα and FOXA1 binding is associated with osteoporosis. Bone. 2009; 45: 289–294.
  • 39
    Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al. New sequence variants associated with bone mineral density. Nat Genet. 2009; 41: 15–17.
  • 40
    Sims AM, Shephard N, Carter K, et al. Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes. J Bone Miner Res. 2008; 23: 499–506.
View Full Article (HTML) Get PDF (57K)